Jack Trottier
@Birchview Capital, Lp
Latest period2024 - Q3ReportedManaged Assets$115.222MTotal holdings61
Assets growth rate6.73%Assets growth rate (2-Q avg)-2.56%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Birchview Capital, Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 61 positions.
Assets under management
The assets under management (AUM) of Birchview Capital, Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 115.222M in assets, with a quarterly growth rate of 6.73% and a 2-quarter average growth rate of -2.56%. The portfolio is managed by Jack Trottier, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
ALKSAlkermes Plc
| 1.22% | $1.399M 50,000 shares@ $27.99 avg price | |
EQTEqt Corporation
| 1.11% | $1.268M 34,619 shares@ $36.64 avg price | New Position |
ATECAlphatec Holdings Inc
| 0.96% | $1.101M 198,000 shares@ $5.56 avg price | Increased 125% |
KALVKalvista Pharmaceuticals Inc
| 0.83% | $949,560 82,000 shares@ $11.58 avg price | Increased 78.27% |
KNSAKiniksa Pharmaceuticals Ltd
| 0.66% | $749,700 30,000 shares@ $24.99 avg price | |
TXG10x Genomics Inc
| 0.59% | $677,400 30,000 shares@ $22.58 avg price | |
HALOHalozyme Therapeutics Inc
| 0.5% | $572,400 10,000 shares@ $57.24 avg price | |
AXDXAccelerate Diagnostics Inc
| 0.49% | $556,158 325,239 shares@ $1.71 avg price | |
CYTKCytokinetics Inc
| 0.46% | $528,000 10,000 shares@ $52.8 avg price | |
INBXInhibrx Biosciences Inc
| 0.44% | $502,843 32,110 shares@ $15.67 avg price | Increased 165.16% |